EpiCast Report: Schizophrenia - Epidemiology Forecast to 2025

EpiCast Report: Schizophrenia - Epidemiology Forecast to 2025

Summary

Schizophrenia is a severe mental disorder that affects an individual’s behaviors, thoughts, and emotions; it is extremely heterogeneous, and no two affected individuals will have the same experience. The disorder is characterized by the presence of positive and negative symptoms. Positive symptoms can be defined as behaviors that are not usually seen in healthy individuals; these symptoms tend to be of a psychotic nature and include hallucinations and delusions. Negative symptoms, on the other hand, are described as a reduction in normal behaviors. People with schizophrenia who exhibit negative symptoms show a lack of motivation, emotions, or interest (apathy), and may sometimes refuse to speak (mute). The severity of these symptoms varies with each affected individual.

GlobalData epidemiologists forecast that the 12-month diagnosed prevalent cases of schizophrenia in the 7MM will increase from 3,298,475 cases in 2015 to 3,462,096 cases in 2025 at an Annual Growth Rate (AGR) of 0.50%. The US has the highest number of 12-month diagnosed prevalent cases of schizophrenia among the individual markets of the 7MM throughout the forecast period, with 1,738,862 cases in 2015 and 1,897,801 cases in 2025, accounting for over 50% of cases in the 7MM.

GlobalData epidemiologists utilized comprehensive, country-specific data from peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the 12-month diagnosed prevalent cases of schizophrenia. Furthermore, GlobalData conducted PMR for schizophrenia in all of the 7MM to both overcome shortcomings of the available literature and better aid market-specific forecasting of schizophrenia. Throughout the 7MM, schizophrenia cases were segmented by age and sex, allowing for a comprehensive, detailed forecast of age- and sex-specific schizophrenia to 2025.

Scope

  • The Schizophrenia EpiCast Report provides an overview of the risk factors and global trends of schizophrenia in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for 12-month diagnosed prevalent cases of schizophrenia segmented by sex and age in these markets.
  • The schizophrenia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The Schizophrenia EpiCast report will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global schizophrenia market.
  • Quantify patient populations in the global schizophrenia market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for schizophrenia therapeutics in each of the markets covered.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Epidemiology
2.1 Disease Background
2.2 Risk Factors and Comorbidities
2.3 Global Trends
2.3.1 US
2.3.2 5EU
2.3.3 Japan
2.4 Forecast Methodology
2.4.1 Sources Used
2.4.2 Forecast Assumptions and Methods
2.4.3 Sources Not Used
2.5 Epidemiological Forecast for Schizophrenia (2015-2025)
2.5.1 12-Month Diagnosed Prevalent Cases of Schizophrenia
2.5.2 Age-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia
2.5.3 Sex-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia
2.5.4 Age-Standardized 12-Month Diagnosed Prevalence of Schizophrenia
2.6 Discussion
2.6.1 Epidemiological Forecast Insight
2.6.2 Limitations of the Analysis
2.6.3 Strengths of the Analysis
3 Appendix
3.1 Bibliography
3.2 Physicians and Specialists Included in This Study
3.2.1 Primary Research - Key Opinion Leaders Interviewed for this Report
3.2.2 Primary Research - Prescriber Survey
3.3 About the Authors
3.3.1 Epidemiologist
3.3.2 Reviewers
3.3.3 Global Director of Therapy Analysis and Epidemiology
3.4 About GlobalData
3.5 About EpiCast
3.6 Disclaimer
1.1 List of Tables
Table 1: Risk Factors and Comorbidities for Schizophrenia
Table 2: 7MM, Sources of 12-Month Diagnosed Prevalence Data
Table 3: 7MM, 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages ≥13 Years, Both Sexes, N, Select Years, 2015-2025
Table 4: 7MM, Age-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages ≥13 Years, Both Sexes, N (Row %), 2015
Table 5: 7MM, Sex-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages ≥13 Years, N (Row %), 2015
Table 6: High-Prescribing Psychiatrists (Non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: 7MM, 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages ≥13 Years, Both Sexes, N, Select Years, 2015-2025
Figure 2: 7MM, Age-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages ≥13 Years, Both Sexes, N, 2015
Figure 3: 7MM, Sex-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages ≥13 Years, N, 2015
Figure 4: 7MM, Age-Standardized 12-Month Diagnosed Prevalence of Schizophrenia (Cases per 100,000 Population), Ages ≥13 Years, Both Sexes, 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook